ABSTRACT
Understanding experiences of a less mobile life under COVID-19 offers insights into the taken-for-granted meanings of mobility in daily life, and into new opportunities for low-carbon mobility transitions associated with working from home. Drawing on 50 written interviews, this article explores meanings attributed to living without commuting during lockdown, examining what people missed and what they appreciated. The results indicate that the majority of respondents miss multiple aspects of daily mobility but have also discovered new experiences and routines that hold their daily life together and make it pleasant. Our findings thereby emphasize an often-neglected aspect in transport research: the complexity and ambivalence of people's relationship with daily mobility. Here, commuting is seen simultaneously as a tiresome burden, but also as a key source of interaction with the wider world which is important in sustaining people's sense of daily balance. Furthermore, ‘compensatory mobilities' emerge as a widespread practice which helps people retain aspects they miss about commuting while working from home. This practice, we suggest, underscores the intrinsic enjoyment associated with being on the move, and is important for unraveling the potential impacts of working from home on people's mobility carbon footprint. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
ABSTRACT
With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns about the safety of systemic treatments of immune-mediated dermatologic disorders has been raised by dermatologists and their patients. We aimed to perform a rapid review of latest American and European guidelines on the use of systemic treatments in patients with immune-mediated dermatologic disorders and confirmed COVID-19 infection and to provide recommendations to inform practice. Based on the current limited guidelines and evidence, systemic corticosteroids should not be abruptly discontinued and the lowest effective dose should be continued. Systemic immunosuppressants (including methotrexate, cyclosporine, azathioprine, cyclophosphamide, and leflunomide), biologics, and sulfasalazine should be withheld in patients with confirmed COVID-19 infection. Whether to continue Janus kinase inhibitors should be determined following a shared decision-making process between dermatologists and patients after considering patients' medical conditions and risk for severe COVID.
ABSTRACT
Scanning electrochemical microscopy (SECM) offers a highly sensitive and convenient approach for electrochemical mapping of interleukin-6 (IL-6), an oral cancer protein biomarker. In this study, we utilized the SECM to map the distribution of IL-6 for imaging different cancer stages on the tissue sections. The SECM results indicated that IL-6 was expressed higher in cancer tissues as compared to normal tissue and hence, SECM can be employed to improve oral cancer diagnosis. Also, IL-6 analysis can be beneficial for predicting the severity of COVID-19 at an early stage to eliminate the potential risks of serious respiratory complications in affected patients. © 2020 The Author(s). Published on behalf of The Electrochemical Society by IOP Publishing Limited.